Segment & Geographic Data
API & CSV Delivery
China Biologic Products Holdings Inc's Business Segments
China Biologic Products Holdings Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Reportable Segments
2
Largest Segment
Bio Pharmaceutical Products
Total Revenue
$ 504
Regions Reported
-
API endpoints for this dataset
https://api.csimarket.com/api/v1/companies/CBPO/segments
https://api.csimarket.com/api/v1/companies/CBPO/geographic
https://api.csimarket.com/api/v1/companies/CBPO/exposure
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Connect Your AI Assistant
Annual Results
Revenue Share by Reportable Segment - FY2019
- Bio Pharmaceutical Products90.9%
- Bio Material Products9.1%
Revenue by Reportable Segment - FY2019
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Bio Pharmaceutical Products | $ 458 | 90.9% |
| Bio Material Products | $ 46 | 9.1% |
Revenue by Product & Service Category - FY2019
- Bio Pharmaceutical Products90.9%
- Plasma Products43.7%
- Human Albumin37.3%
- Human Immunoglobulin for Intravenous Injection23.3%
- Other Immunoglobulin Products14.3%
- Others10.7%
- Bio Material Products8.7%
- Artificial Dura Mater8.4%
- Placenta Polypeptide5.4%
- Other0.7%
Revenue by Product & Service Category - FY2019
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Bio Pharmaceutical Products | $ 458 | 90.9% |
| Plasma Products | $ 220 | 43.7% |
| Human Albumin | $ 188 | 37.3% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
7 more categories available
Sign in to unlock the full China Biologic Products Holdings Inc dataset.
Description of China Biologic Products Holdings Inc
China Biologic Products Holdings Inc is a biopharmaceutical company that focuses on the research, development, manufacture, and sale of plasma-based products in China.
The company's product portfolio includes various dosage forms, including IV solutions and lyophilized powder injectables derived from human plasma.
In addition, the company offers research and development services to its customers.
China Biologic Products Holdings Inc was founded in 1971 and is headquartered in Beijing, China.
The company has a presence in over 30 provinces and municipalities across China and provides products to customers in over 60 countries.
The company is publicly traded on the NASDAQ stock exchange under the symbol CBPO.
The company's product portfolio includes various dosage forms, including IV solutions and lyophilized powder injectables derived from human plasma.
In addition, the company offers research and development services to its customers.
China Biologic Products Holdings Inc was founded in 1971 and is headquartered in Beijing, China.
The company has a presence in over 30 provinces and municipalities across China and provides products to customers in over 60 countries.
The company is publicly traded on the NASDAQ stock exchange under the symbol CBPO.
China Biologic Products Holdings Inc. is a premier player in the biopharmaceutical sector in China, primarily centered on the research, development, manufacturing, and marketing of an extensive array of plasma-derived biopharmaceutical products. The companys offerings are organized into distinct segments, covering a comprehensive suite of products and services that underline its commitment to addressing critical healthcare needs.
Segments
1. Human Plasma-based Products
This segment is the cornerstone of China Biologic’s portfolio, encompassing a wide variety of products derived from human plasma. The primary offerings include:
- Human Albumin: Essential for maintaining oncotic pressure in the blood, human albumin therapy is vital for patients suffering from burns, trauma, liver cirrhosis, and other conditions that lead to fluid loss.
- Immunoglobulin Products: These are critical for patients with immune deficiencies or those undergoing treatments that suppress immune function. The varieties offered include:
- Intravenous Immunoglobulin (IVIG): Used to treat a range of autoimmune and immunodeficiency disorders.
- Subcutaneous Immunoglobulin (SCIG): An alternative to IVIG for patients who benefit from a self-administered therapy.
- Hepatitis B Immunoglobulin: Utilized in post-exposure prophylaxis for hepatitis B virus.
- Coagulation Factors: Indispensable for managing blood disorders, especially hemophilia. Key products include:
- Fibrinogen Concentrate: Important in managing bleeding in patients with fibrinogen deficiency.
- Prothrombin Complex Concentrate: Used to treat bleeding episodes in patients receiving anticoagulation therapy.
- Factor VIII: A crucial factor for hemophilia A patients.
Other Plasma-based Products
This segment expands the companys reach to include various other plasma-derived products that cater to both medical and non-medical needs. Noteworthy products include:
- Human Rabies Immunoglobulin: Essential for post-exposure treatment in rabies cases.
- Tetanus Immunoglobulin: Used for the prevention of tetanus in at-risk populations.
- Varicella-Zoster Immunoglobulin: Important for protecting immunocompromised patients from chickenpox complications.
Regenerative Medicine
This emerging segment highlights the companys commitment to innovative therapeutic avenues. The products under this category are derived from stem cell research and have potential applications in treating various conditions, including:
- Neurological Diseases: Such as spinal cord injuries and neurodegenerative disorders.
- Orthopedic Conditions: Tissue regeneration in injuries and degenerative bone diseases.
- Cardiovascular Diseases: With the aim of repairing damage to heart tissue following heart attacks.
Products
- Human Albumin: The companys product line includes both human serum albumin and advanced human recombinant albumin variants tailored for clinical use.
- Immunoglobulin: A robust selection of immunoglobulin therapies designed to respond effectively to a multitude of clinical scenarios, enhancing patient immunity.
- Coagulation Factors: A comprehensive suite designed to ensure effective treatment options for individuals with bleeding disorders.
- Other Plasma-based Products: These specialized products provide essential therapeutic support across a range of infectious diseases.
- Stem Cell Products: These biologics, including stromal vascular fraction (SVF) and placental mesenchymal stem cells (PMSCs), are promising tools in regenerative therapies.
Services
1. Plasma Collection Services
China Biologic currently maintains over 40 plasma collection centers across the nation. These centers are critical for sourcing high-quality plasma from voluntary donors, ensuring a steady supply for their product lines.
Contract Manufacturing Services
The company offers its expertise through contract manufacturing services tailored for other biopharmaceutical firms. These services encompass a broad range of capabilities, including:
- Processing Services: Utilizing advanced technologies in the production of plasma-derived products.
- Testing and Quality Assurance: Employing rigorous testing protocols to guarantee product safety and efficacy.
- Analytical Services: Providing in-depth analytical support to ensure compliance with regulatory standards.
Conclusion
In summary, China Biologic Products Holdings Inc. is a formidable entity in the biopharmaceutical landscape, excelling in the manufacture and supply of plasma-based products. With a diverse portfolio ranging from human albumin and immunoglobulins to coagulation factors and regenerative medicine solutions, the company is well-positioned to meet the evolving needs of global healthcare. Its ancillary services, including plasma collection and contract manufacturing, further enhance its operational capabilities, solidifying its role as a key contributor to the health and well-being of patients both in China and beyond.
Segments
1. Human Plasma-based Products
This segment is the cornerstone of China Biologic’s portfolio, encompassing a wide variety of products derived from human plasma. The primary offerings include:
- Human Albumin: Essential for maintaining oncotic pressure in the blood, human albumin therapy is vital for patients suffering from burns, trauma, liver cirrhosis, and other conditions that lead to fluid loss.
- Immunoglobulin Products: These are critical for patients with immune deficiencies or those undergoing treatments that suppress immune function. The varieties offered include:
- Intravenous Immunoglobulin (IVIG): Used to treat a range of autoimmune and immunodeficiency disorders.
- Subcutaneous Immunoglobulin (SCIG): An alternative to IVIG for patients who benefit from a self-administered therapy.
- Hepatitis B Immunoglobulin: Utilized in post-exposure prophylaxis for hepatitis B virus.
- Coagulation Factors: Indispensable for managing blood disorders, especially hemophilia. Key products include:
- Fibrinogen Concentrate: Important in managing bleeding in patients with fibrinogen deficiency.
- Prothrombin Complex Concentrate: Used to treat bleeding episodes in patients receiving anticoagulation therapy.
- Factor VIII: A crucial factor for hemophilia A patients.
Other Plasma-based Products
This segment expands the companys reach to include various other plasma-derived products that cater to both medical and non-medical needs. Noteworthy products include:
- Human Rabies Immunoglobulin: Essential for post-exposure treatment in rabies cases.
- Tetanus Immunoglobulin: Used for the prevention of tetanus in at-risk populations.
- Varicella-Zoster Immunoglobulin: Important for protecting immunocompromised patients from chickenpox complications.
Regenerative Medicine
This emerging segment highlights the companys commitment to innovative therapeutic avenues. The products under this category are derived from stem cell research and have potential applications in treating various conditions, including:
- Neurological Diseases: Such as spinal cord injuries and neurodegenerative disorders.
- Orthopedic Conditions: Tissue regeneration in injuries and degenerative bone diseases.
- Cardiovascular Diseases: With the aim of repairing damage to heart tissue following heart attacks.
Products
- Human Albumin: The companys product line includes both human serum albumin and advanced human recombinant albumin variants tailored for clinical use.
- Immunoglobulin: A robust selection of immunoglobulin therapies designed to respond effectively to a multitude of clinical scenarios, enhancing patient immunity.
- Coagulation Factors: A comprehensive suite designed to ensure effective treatment options for individuals with bleeding disorders.
- Other Plasma-based Products: These specialized products provide essential therapeutic support across a range of infectious diseases.
- Stem Cell Products: These biologics, including stromal vascular fraction (SVF) and placental mesenchymal stem cells (PMSCs), are promising tools in regenerative therapies.
Services
1. Plasma Collection Services
China Biologic currently maintains over 40 plasma collection centers across the nation. These centers are critical for sourcing high-quality plasma from voluntary donors, ensuring a steady supply for their product lines.
Contract Manufacturing Services
The company offers its expertise through contract manufacturing services tailored for other biopharmaceutical firms. These services encompass a broad range of capabilities, including:
- Processing Services: Utilizing advanced technologies in the production of plasma-derived products.
- Testing and Quality Assurance: Employing rigorous testing protocols to guarantee product safety and efficacy.
- Analytical Services: Providing in-depth analytical support to ensure compliance with regulatory standards.
Conclusion
In summary, China Biologic Products Holdings Inc. is a formidable entity in the biopharmaceutical landscape, excelling in the manufacture and supply of plasma-based products. With a diverse portfolio ranging from human albumin and immunoglobulins to coagulation factors and regenerative medicine solutions, the company is well-positioned to meet the evolving needs of global healthcare. Its ancillary services, including plasma collection and contract manufacturing, further enhance its operational capabilities, solidifying its role as a key contributor to the health and well-being of patients both in China and beyond.